Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Cidofovir

Cidofovir
Contact us for more batch information
Select Batch
Purity:99.24%
Resource Download

Cidofovir

Catalog No. T6244Cas No. 113852-37-2
Cidofovir ((S)-HPMPC) inhibits virus replication by specific inhibition of viral DNA synthesis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
5 mg$31In Stock
10 mg$48In Stock
25 mg$68In Stock
50 mg$81In Stock
100 mg$127In Stock
200 mg$185In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Cidofovir"

Product Introduction

Bioactivity
Description
Cidofovir ((S)-HPMPC) inhibits virus replication by specific inhibition of viral DNA synthesis.
In vitro
Cidofovir inhibits human cytomegalovirus (HCMV) infection in cultured cells. Cidofovir is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively. [1] Cidofovir also inhibits herpes simplex virus infection. In addition, Cidofovir blocks cell fusion induced by HSV-1 in monkey kidney cells and blocks the expression of HSV-l-specific proteins and the synthesis of viral DNA. [3]
In vivo
Cidofovir (5 mg/kg/day) subcutaneously for 5 days significantly reduces average virus infectivity titer in blood, spleen, lung and salivary gland in infected guinea pigs. Cidofovir significantly reduces lymphocytosis and average tissue indexe of spleen in infected animals. [2]. Cidofovir suppresses all manifestations (skin lesions, paralysis of the hind legs, and mortality) of hairless mice infected intracutaneously with HSV-1 or HSV-2. The most remarkable feature of Cidofovir is that a single administration of the compound, even as late as 4 days after infection, conferees significant protection against HSV-1 or HSV-2 infection. [4] Cidofovir inhibits growth of the highly aggressive melanoma tumor arising from mouse melanoma B16 cells grafted subcutaneously in C57B16/J mice. [5]
Kinase Assay
EGFR kinase assays: In vitro inhibitory enzyme kinetic assays using recombinant EGFR L858R/T790M and WT protein and are performed using the ATP/NADH coupled assay system in a 96-well format. WZ4002 is added to determine its inhibitory effects.
AliasHPMPC, GS 0504, (S)-HPMPC
Chemical Properties
Molecular Weight279.19
FormulaC8H14N3O6P
Cas No.113852-37-2
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
H2O: 5 mg/mL (17.91 mM)
DMSO: < 1 mg/mL (insoluble or slightly soluble) (3.58 mM)
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM3.5818 mL17.9090 mL35.8179 mL179.0895 mL
H2O
1mg5mg10mg50mg
5 mM0.7164 mL3.5818 mL7.1636 mL35.8179 mL
10 mM0.3582 mL1.7909 mL3.5818 mL17.9090 mL
20 mM0.1791 mL0.8954 mL1.7909 mL8.9545 mL
50 mM0.0716 mL0.3582 mL0.7164 mL3.5818 mL
100 mM0.0358 mL0.1791 mL0.3582 mL1.7909 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords